Division of WerfenLife Group SA
Latest From Instrumentation Laboratory
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.
There is a need for assays to help guide therapy with the growing number of anticoagulant drugs on the market, but without clearer FDA guidelines development will be a challenge, companies and labs tell the agency.
In Vitro Diagnostics
- Hematology, Coagulation
- Diagnostic Equipment & Supplies
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- North America
- Parent & Subsidiaries
- WerfenLife Group SA
- Senior Management
- Contact Info
Phone: (800) 955-9525
180 Hartwell Rd.
Bedford, MA 01730
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.